Pancrelipase
Sponsors
Ohdan Hideki, Digestive Care, Inc., Mylan Inc., American Academy of Family Physicians, University of Colorado, Denver
Conditions
Cases of adjuvant chemotherapy administered after gastrectomy for Stage2 and 3 gastric cancer
Gastric CancerCeliac DiseaseChronic PancreatitisCystic FibrosisDigestive System DiseasesExocrine Pancreatic InsufficiencyExocrine Pancreatic Insufficiency (EPI)Irritable Bowel Syndrome
Phase 1
Phase 2
Trial of Pancreatic Enzyme Supplements (Pancrelipase) for Treating Pain in Patients With Chronic Pancreatitis
WithdrawnNCT02706236
Start: 2016-04-30End: 2018-12-31Updated: 2018-02-27
Study of Pancreatic Enzyme Replacement on Completion of Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma
TerminatedNCT03469258
Start: 2018-04-13End: 2019-10-01Updated: 2020-08-03
Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Insufficiency
Active, not recruitingNCT04098237
Start: 2020-12-17End: 2027-01-01Updated: 2026-01-23
The efficacy and safety of pancrelipase in patients undergoing adjuvant chemotherapy after gastrectomy: A multicenter, prospective, open-label study.
RecruitingJPRN-jRCT1061250077
Start: 2026-05-18Target: 100Updated: 2026-06-29
Phase 4
Intraduodenal Aspiration Study to Assess the Bioavailability of Oral Pancrecarb® Compared to Placebo Control
TerminatedNCT00744250
Start: 2008-08-31End: 2010-05-31Updated: 2013-02-22
Irritable Bowel Syndrome Evaluation and Treatment in Primary Care
CompletedNCT01641341
Start: 2010-11-30End: 2012-03-31Updated: 2019-01-23
Pancreatic Enzyme Supplementation for Celiac Disease
TerminatedNCT02475369
Start: 2015-05-31End: 2019-12-31Updated: 2021-05-12
A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)
TerminatedNCT03859869
Start: 2020-02-25End: 2022-03-23Updated: 2023-06-05
A Study to Compare US Marketed Creon Manufactured With a Modernized Process at an Alternate Manufacturing Site and Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Participants With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
CompletedNCT03924947
Start: 2019-10-23End: 2022-07-11Updated: 2023-09-28
Unknown Phase
Bioavailability of Pancreatic Enzymes in the Human Upper Intestine (Duodenum and Jejunum)
TerminatedNCT00749099
Start: 2007-04-30End: 2010-09-30Updated: 2013-02-22
Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
CompletedNCT01427712
Start: 2011-08-31End: 2018-03-31Updated: 2022-06-10
Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic Fibrosis
CompletedNCT02372383
Start: 2014-10-31End: 2016-06-30Updated: 2021-02-11